We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amryt Pharma Plc | LSE:AMYT | London | Ordinary Share | GB00BKLTQ412 | ORD 6P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 143.00 | 151.00 | 170.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMAMYT
RNS Number : 5410D
Amryt Pharma PLC
07 July 2016
7 July, 2016
Amryt Pharma plc
("Amryt" or the "Company")
Result of AGM
Amryt Pharma plc (AIM: AMYT, ESM: AYP), the clinical stage specialty pharma company focused on best in class treatments for orphan diseases, announces that all resolutions put to shareholders were duly passed at its Annual General Meeting held earlier today.
Enquiries:
Amryt Pharma plc C/o FTI Consulting Joe Wiley, CEO Rory Nealon, CFO/COO +44 (0) 20 Shore Capital 7408 4090 Nomad and Joint Broker Bidhi Bhoma, Edward Mansfield +353 (1) 679 Davy 6363 ESM Adviser and Joint Broker John Frain, Anthony Farrell +44 (0) 20 Stifel 7710 7600 Joint Broker Jonathan Senior, Ben Maddison +44 (0) 20 FTI Consulting 3727 1000 Simon Conway, Brett Pollard
About Amryt Pharma plc - see www.amrytpharma.com
Amryt Pharma is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or 'orphan' diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, propriety new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.
Amryt's lead product, Episalvan(R), received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016. Amryt intends to further develop Episalvan(R) as a new treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. Amryt is currently planning a phase III study of Episalvan(R) in EB, which has been granted US and EU orphan drug designation.
Amryt's earlier stage products are focused on developing novel, next generation somatostatin analogue ("SSA") peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need. These include acromegaly and Cushing's disease.
The Company joined AIM and Dublin's ESM in April 2016 following the reverse takeover of Fastnet Equity PLC.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGEAPXXEFLKEEF
(END) Dow Jones Newswires
July 07, 2016 07:54 ET (11:54 GMT)
1 Year Amryt Pharma Chart |
1 Month Amryt Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions